There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Akebia Therapeutics (NASDAQ: AKBA), Verastem (NASDAQ: VSTM) and Summit Therapeutics (NASDAQ: SMMT) with bullish sentiments.
Akebia Therapeutics (NASDAQ: AKBA)
In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Akebia Therapeutics (NASDAQ: AKBA), with a price target of $22. The company’s shares closed yesterday at $9.62, close to its 52-week low of $8.93.
According to TipRanks.com, Arce is a 5-star analyst with an average return of 27.3% and a 46.6% success rate. Arce covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Collegium Pharmaceutical, and Conatus Pharmaceuticals.
Akebia Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $24.
See today’s analyst top recommended stocks >>
Verastem (NASDAQ: VSTM)
In a report released today, Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on Verastem (NASDAQ: VSTM), with a price target of $10. The company’s shares closed yesterday at $5.52, close to its 52-week high of $5.90.
Ramakanth observed:
“We believe that the upcoming approval of duvelisib on or before the PDUFA date of October 5 could be a major catalyst for the stock.”
According to TipRanks.com, Ramakanth is a 4-star analyst with an average return of 8.2% and a 41.5% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals Inc, IntelGenx Technologies, and Trillium Therapeutics.
Currently, the analyst consensus on Verastem is Strong Buy and the average price target is $13.33, representing a 141.5% upside.
In a report released yesterday, Oppenheimer also assigned a Buy rating to the stock with a $15 price target.
Summit Therapeutics (NASDAQ: SMMT)
In a report released today, Debjit Chattopadhyay from H.C. Wainwright maintained a Buy rating on Summit Therapeutics (NASDAQ: SMMT), with a price target of $20. The company’s shares closed yesterday at $13.26.
According to TipRanks.com, Chattopadhyay is a 3-star analyst with an average return of 2.9% and a 48.6% success rate. Chattopadhyay covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Mersana Therapeutics Inc, and Voyager Therapeutics Inc.
Summit Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $28.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
